← Search & browse all drugs
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Artemisinin and derivatives, combinations
artenimol and piperaquine
P01BF05
Forms & Strengths
- Artenimol 20 mg / Piperaquine tetraphosphate 160 mg oral tablet
- Artenimol 40 mg / Piperaquine tetraphosphate 320 mg oral tablet
Adult Dosing
- Uncomplicated malaria: 3-day treatment course given as once daily
- Total target dose: Artenimol 2.4 mg/kg/day and Piperaquine 18 mg/kg/day over 3 days
Pediatric Dosing
- Weight-based dosing for children weighing >= 5 kg
- Administered once daily for 3 consecutive days following the national/WHO weight-band table
Indications
- Treatment of acute uncomplicated Plasmodium falciparum malaria
Mechanism of Action
- Artenimol (dihydroartemisinin) produces rapid parasite clearance via endoperoxide moiety generating free radicals
- Piperaquine provides longer-duration blood schizonticide activity through inhibition of heme polymerization
Contraindications
- Known hypersensitivity to artemisinin derivatives or piperaquine
- History of familial prolongation of QTc interval or congenital long QT syndrome
- History of symptomatic arrhythmias or clinically significant bradycardia
- Severe forms of malaria according to WHO criteria
- Concomitant administration of drugs that prolong the QT interval
Adverse Reactions
- QTc prolongation
- Headache
- Dizziness
- Anorexia
- Asthenia
- Nausea and vomiting
- Palpitations
- Sinus bradycardia
Drug Interactions
- Avoid strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) and inducers (e.g., rifampin, carbamazepine)
- Avoid concomitant use with QT-prolonging drugs (e.g., antiarrhythmics, antipsychotics, macrolide antibiotics)
- Caution with drugs metabolized by CYP2C19 or CYP2D6 due to potential inhibitory effects of piperaquine
Curated Content: Needs Vetting Before Put to Clinical Use